A new research paper was published in Oncotarget, titled, "Neurotrophic-tyrosine receptor kinase gene fusion in papillary thyroid cancer: A clinicogenomic biobank and record linkage study from Finland ...
NTRK gene fusions result from chromosomal rearrangements that link the kinase domain of NTRK1, NTRK2 or NTRK3 to various partner genes, generating constitutively active tropomyosin receptor kinases ...
Tropomyosin receptor kinases (TRKs), encoded by neurotrophic receptor tyrosine kinase (NTRK) genes, are involved in cell proliferation, differentiation and apoptosis, and are validated therapeutic ...
The Food and Drug Administration will review Augtyro for potential approval in children and adults with advanced solid cancers that harbor NTRK gene fusions. The Food and Drug Administration (FDA) ...
The Food and Drug Administration recently approved Augtyro for the treatment of patients ages 12 and older with solid tumors harboring an NTRK gene fusion. With its June approval of Augtyro ...
Neurotrophic tyrosine receptor kinase (NTRK)–positive locally advanced or metastatic solid tumors can now be treated with the first FDA-approved treatment option. On June 13, the FDA announced the ...
“Estimates of the frequency of NTRK gene fusion in large cohorts of patients with solid tumors come from a limited number of studies. [...]. We aimed to address this gap by evaluating patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results